Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1236-1241

  Zalman, L S ^a   Brothers, M A ^a   Dragovich, P S ^a   Zhou, R ^a   Prins, T J ^a   Worland, S T ^a   Patick, A K ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; PROTEINASE INHIBITOR; RUPINTRIVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; CYTOKINES; HELA CELLS; HUMANS; ISOXAZOLES; MICROBIAL SENSITIVITY TESTS; PYRROLIDINONES; RHINOVIRUS; TIME FACTORS; VIRAL PROTEINS;

EID: 0034050610     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1236-1241.2000     Document Type: Article

References (45)

1. Andries, K., B. Dewindt, J. Snoeks, R. Willebrords, K. Van Eemeren, R. Stokbroekx, and P. A. J. Janssen. 1992. In vitro activity of pirodavir (R77975), a substituted phenoxy-pyridazinamine with broad-spectrum anti-picornaviral activity. Antimicrob. Agents Chemother. 36:100-107.
2. Arruda, E., C. E. Crump, S. D. Marlin, V. J. Merluzzi, and F. G. Hayden. 1992. In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrob. Agents Chemother. 36:1186-1191.
3. Arruda, E., T. R. Boyle, B. Winther, D. C. Pevear, J. M. Gwaltney, Jr., and F. G. Hayden. 1995. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J. Infect. Dis. 171:1329-1333.
4. Arruda, E., and F. G. Hayden. 1995. Clinical studies of antiviral agents for picornaviral infections, p. 321-355. In D. J. Jeffries and E. De Clerq (ed.), Antiviral chemotherapy. John Wiley & Sons Ltd., Chichester, N.Y.
5. Bardin, P. G., S. L. Johnston, G. Sanderson, B. S. Robinson, M. A. Pickett, D. J. Fraenkel, and S. T. Holgate. 1994. Detection of rhinovirus infection of the nasal mucosa by oligonucleotide in situ hybridization. Am. J. Respir. Cell Biol. 10:207-213.
6. Biagioli, C. M., P. Kaul, I. Singh, and R. B. Turner. 1999. The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. Free Rad. Biol. Med. 26:454-462.
7. Couch, R. B. 1990. Rhinoviruses, p. 607-629. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
8. Diana, G. D., P. Rudewicz, D. C. Pevear, T. J. Nitz, S. C. Aldous, D. J. Aldous, D. T. Robinson, T. Draper, F. J. Dutko, C. Aldi, G. Gendron, R. C. Oglesby, D. L. Volkots, M. Reuman, T. R. Bailey, R. Czerniak, T. Block, R. Roland, and J. Oppermann. 1995. Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J. Med. Chem. 38:1355-1371.
9. Douglas, R. G., T. R. Cate, P. J. Gerone, and R. B. Couch. 1966. Quantitative rhinovirus shedding patterns in volunteers. Am. Rev. Respir. Dis. 94:159-167.
10. Dragovich, P. S., T. J. Prins, R. Zhou, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. E. Ford, J. W. Meador III, R. A. Ferre, and S. T. Worland. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J. Med. Chem. 42:1203-1212.
11. 1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42:1213-1224.
12. Dragovich, P. S., S. E. Webber, R. E. Babine, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, S. H. Reich, T. J. Prins, J. T. Marakovits, E. S. Littlefield, R. Zhou, J. Tikhe, C. E. Ford, M. Wallace, J. W. Meador III, R. A. Ferre, E. L. Brown, S. L. Binford, J. E. V. Harr, D. M. DeLisle, and S. T. Worland. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem. 41:2806-2818.
13. Dragovich, P. S., S. E. Webber, R. E. Babine, S. A. Fuhrman, A. K. Patick, D. A. Matthews, S. H. Reich, J. T. Marakovits, T. J. Prins, R. Zhou, J. Tikhe, E. S. Littlefield, T. M. Bleckman, M. Wallace, T. Little, C. E. Ford, J. W. Meador III, R. A. Ferre, E. L. Brown, S. L. Binford, D. M. DeLisle, and S. T. Worland. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 41:2819-2834.
14. Dragovich, P. S., R. Zhou, D. J. Skalitzky, S. A. Fuhrman, A. K. Patick, C. E. Ford, J. W. Meador III, and S. T. Worland. 1999. Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. 1. Optimization of tripeptides incorporating N-terminal amides. Bioorg. Med. Chem. 7:589-598.
15. Fromtling, R. A., and J. Castañer. 1997. VP-63843 Pleconaril WIN-63843. Drugs Future 22:40-44.
16. Hayden, F. G., R. S. Fritz, M. C. Lobo, W. G. Alvord, W. Strober, and S. E. Straus. 1998. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J. Clin. Investig. 101:643-649.
17. Hayden, F. G., G. J. Hipskind, D. H. Woerner, G. F. Eisen, M. Janssen, P. A. J. Janssen, and K. Andries. 1995. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39:290-294.
18. Hayden, F. G., A. D. M. E. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zamanivir in the treatment of influenzavirus infections. N. Engl. J. Med. 337:874-880.
19. Hayden, F. G., K. Andries, and P. A. J. Janssen. 1992. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36:727-732.
20. Heinz, B. A., J. Tang, J. M. Labus, F. W. Chadwell, S. W. Kaldor, and M. Hammond. 1996. Simple in vitro translation assay to analyze inhibitors of rhinovirus proteases. Antimicrob. Agents Chemother. 40:267-270.
21. Johnston, S. L., A. Papi, P. J. Bates, J. G. Mastronarde, M. M. Monick, and G. W. Hunninghake. 1998. Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J. Immunol. 160:6172-6181.
22. Kaldor, S. W., M. Hammond, B. A. Dressman, J. M. Labus, F. W. Chadwell, A. D. Kline, and B. A. Heinz. 1995. Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease. Bioorg. Med. Chem. Lett. 5:2021-2026.
23. Kong, J.-S., S. Venkatraman, K. Furness, S. Nimkar, T. A. Shepherd, Q. M. Wang, J. Aube, and R. P. J. Hanzlik. 1998. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J. Med. Chem. 41:2579-2587.
24. Matthews, D. A., P. S. Dragovich, S. E. Webber, S. A. Fuhrman, A. K. Patick, L. S. Zalman, T. Hendrickson, T. J. Prins, J. T. Marakovits, R. Zhou, J. Tikhe, C. E. Ford, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, M. A. Brothers, D. M. DeLisle, and S. T. Worland. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA 96:11000-11007.
25. Matthews, D. A., W. W. Smith, R. A. Ferre, B. Condon, G. Budahazi, W. Sisson, J. E. Villafranca, C. A. Janson, H. E. McElroy, C. L. Gribskov, and S. Worland. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761-771.
26. Melnick, J. L. 1990. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 549-605. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
27. Noah, T. L., F. W. Henderson, I. A. Wortman, R. B. Devlin, J. Handy, H. S. Koren, and S. Becker. 1995. Nasal cytokine production in viral acute upper respiratory infection of childhood. J. Infect. Dis. 171:584-592.
28. Otto, M. J., M. P. Fox, M. J. Fancher, M. F. Kuhrt, G. D. Diana, and M. A. McKinlay. 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:883-886.
29. Patick, A., and K. Potts. 1998. Protease inhibitors as antiviral agents. Clin. Microbiol. Rev. 11:614-627.
30. Patick, A. K., S. L. Binford, M. A. Brothers, R. L. Jackson, C. E. Ford, M. D. Diem, F. Maldonado, P. S. Dragovich, R. Zhou, T. J. Prins, S. A. Fuhrman, J. W. Meador, L. S. Zalman, D. A. Matthews, and S. T. Worland. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43:2444-2450.
31. Pitkaranta, A., and F. G. Hayden. 1998. What's new with common colds? Pathogenesis and diagnosis. Infect. Med. 15:50-59.
32. Proud, D., J. M. Gwaltney, Jr., J. O. Hendley, C. A. Dinarello, S. Gillis, and R. P. Schleimer. 1994. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J. Infect. Dis. 169:1007-1013.
33. Roseler, S., G. Holtappels, M. Wagenmann, and C. Bachert. 1995. Elevated levels of interleukins IL-1b, IL-6 and IL-8 in naturally acquired viral rhinitis. Eur. Arch. Otorhinolaryngol. 252(Suppl. 1):S61-S63.
34. Rueckert, R. R. 1990. Picornaviridae and their replication, p. 507-548. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
35. Shepherd, T. A., G. A. Cox, E. McKinney, J. Tang, M. Wakulchik, R. E. Zimmerman, and E. C. Villarreal. 1996. Small peptidic aldehyde inhibitors of human rhinovirus 3C protease. Bioorg. Med. Chem. Lett. 6:2893-2896.
36. Skern, T., W. Sommergruber, D. Blaas, P. Gruendler, F. Fraundorfer, C. Pieler, I. Fogy, and E. Kuechler. 1985. Human rhinovirus 2: complete nucleotide sequence and proteolytic processing signals in the capsid protein region. Nucleic Acids Res. 13:2111-2126.
37. Stanway, G., P. J. Hughes, R. C. Mountford, P. D. Minor, and J. W. Almond. 1984. The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res. 12:7859-7875.
38. Subauste, M. C., D. B. Jacoby, S. M. Richards, and D. Proud. 1995. Infection of a human respiratory epithelial cell line with rhinovirus; induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J. Clin. Investig. 96:549-557.
39. Turner, R. B., K. W. Weingand, C.-H. Yen, and D. W. Leedy. 1998. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin. Infect. Dis. 26:840-846.
40. Wang, Q. M., R. B. Johnson, L. N. Hungheim, J. D. Cohen, and E. C. Villarreal. 1998. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob. Agents Chemother. 42:916-920.
41. Webber, S., J. Tikhe, S. T. Worland, S. A. Fuhrman, T. F. Hendrickson, D. A. Matthews, R. A. Love, A. K. Patick, J. W. Meador, R. A. Ferre, E. L. Brown, D. M. DeLisle, C. E. Ford, and S. L. Binford. 1996. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J. Med. Chem. 39:5072-5082.
42. 1 glutamine isosteric replacements. J. Med. Chem. 41:2786-2805.
43. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
44. Werner, G., B. Rosenwirth, E. Bauer, J. M. Seifert, F. J. Werner, and J. Besemer. 1986. Molecular cloning and sequence determination of the genomic regions encoding protease and genome-linked protein of three picornaviruses. J. Virol. 57:1084-1093.
45. Zhu, Z., W. Tang, A. Ray, Y. Wu, O. Einarsson, M. L. Landry, J. J. Gwaltney, and J. A. Elias. 1996. Rhinovirus stimulation of interleukin-6 in vivo and in vitro: evidence for nuclear factor kappa B dependent transcriptional activation. J. Clin. Investig. 97:421-430.